Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis

American Journal of Cardiology

Volumn 83, Issue 6, 1999, Pages 852-856

  De Maat, Moniek P M ^a,c   Jukema, J Wouter ^b,c   Ye, Shu ^a,c   Zwinderman, Aeilko H ^a,c   Moghaddam, Payman Hanifi ^a,c   Beekman, Marian ^a,c   Kastelein, John J P ^c,d   Van Boven, Ad J ^c,e   Bruschke, Albert V G ^b,c,f   Humphries, Steve E ^c,g   Kluft, Cornelis ^a,c   Henney, Adriano M ^a,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Atherosclerosis Inflammation A   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^g Centre for Cardiovascular Genetics   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRAVASTATIN; STROMELYSIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; DISEASE-FREE SURVIVAL; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MULTICENTER STUDIES; POLYMORPHISM, GENETIC; PRAVASTATIN; PROMOTER REGIONS (GENETICS); RANDOMIZED CONTROLLED TRIALS; RECURRENCE; TREATMENT OUTCOME;

EID: 0033002576     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)01073-X     Document Type: Article

References (20)

1. Sing C.F., Moll P.P. Genetics of atherosclerosis. Ann Rev Gen. 24:1990;171-187.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
3. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
4. Jukema J.W., Bruschke A.V.G., van Boven A.J., Reiber J.H., Bal E.T., Zwinderman A.H., Jansen H., Boerma G.J., van Rappard F.M., Lie K.I. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. "The regression growth evaluation statin study" (REGRESS). Circulation. 91:1995;2528-2540.
5. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Wun C.-C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1995;1001-1009.
6. Henney A.M., Wakeley P.R., Davies M.J., Foster K., Hembry R., Murphy G., Humphries S. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sciences USA. 88:1991;8154-8158.
7. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 94:1994;2493-2503.
8. Galis Z.S., Muszynski M., Sukhova G.K., Simon-Morrissey E., Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann NY Acad Sciences. 748:1995;501-507.
9. Galis Z.S., Sukhova G.K., Kranzhofer R., Clark S., Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinase. Proc Natl Acad Sciences USA. 92:1995;402-406.
10. Brown D.L., Hibbs M.S., Kearney M., Loushin C., Isner J.M. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation. 91:1995;2125-2131.
11. Nikkari S.T., O'Brien K.D., Furguson M., Hatsukami T., Welgus H.G., Aplers C.E., Clowes A.W. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation. 92:1995;1393-1398.
12. Ye S., Eriksson P., Hamsten A., Kurkinen M., Humphries S.E., Henney A.M. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 271:1996;13055-13060.
13. Ye S., Watts G.F., Mandalia S., Humphries S.E., Henney A.M. Genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J. 73:1995;209-215.
14. Humphries S.E., Luong L.A., Talmud P.J., Frick M.H., Kesäniemi, Pasternack A., Taskinen M.R., Syvänne M. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Atherosclerosis. 139:1998;49-56.
15. Kobashigawa J.A., Katznelson S., Laks H., Johnson J.A., Yeatman L., Wang X.M., Chia D., Terasaki P.I., Sabad A., Cogert G.A. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 333:1995;621-627.
16. Smeets B., Poddighe J., Brunner H., Ropers H.H., Wieringa B. Tight linkage between myotonic dystrophy and apolipoprotein E genes revealed with allele-specific oligonucleotides. Human Genet. 80:1988;49-52.
17. Luc G., Bard J.-M., Arveiler D., Evans A., Cambou J.P., Bingham A., Amouyel P., Schaffer P., Ruidavets J.B., Cambien F. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study. Arterioscler Thromb. 14:1994;1412-1419.
18. 9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. Circulation. 94:1996;1913-1918.
19. Kuivenhoven J.A., Jukema J.W., Zwinderman A.H., de Knijff P., McPherson R., Bruschke A.V.G., Lie K.I., Kastelein J.J.P. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med. 338:1998;86-93.
20. De Maat M.P.M., Kastelein J.J.P., Jukema J.W., Zwinderman A.H., Jansen H., Groenemeier B., Bruschke A.V.G., Kluft C. -455G/A polymorphism of the β-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men. Arterioscler Thromb Vasc Biol. 18:1998;265-271.